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Melanoma is a malignant tumor that develops from melanocytes, which are 
pigmented cells primarily found in the epidermis, eye, and mucosal epithelia. Melanomas 
can occur in any tissue containing melanocytes. Although both cutaneous and uveal 
melanomas are derived from melanocytes, they have significant differences in terms of 
genetic alterations, metastatic pattern, tumorigenesis, and therapeutic response.  
In this dissertation, I present the results of studies that explore the role of the 
small GTPase ARF6 in cutaneous and uveal melanoma. These studies show that ARF6 is 
required both for invasion and metastasis in cutaneous melanoma and for orchestrating 
oncogenic G protein-mediated signaling pathways that promote uveal melanoma cell 
proliferation. In cutaneous melanoma cells, WNT5A-FZD4-LRP6 signaling activates 
ARF6 via the guanine nucleotide exchange factor (GEF) GEP100. ARF6 activation 
promotes the release of -catenin from cell-surface N-cadherin, thereby increasing the 
pool of cytoplasmic and nuclear -catenin with a subsequent induction of transcription, 
invasion, and metastasis. As WNT signaling is implicated in many cancers, these findings 
suggest that a WNT-ARFGEF-ARF signaling module may play an important role in the 
metastasis of multiple cancers. 
Uveal melanoma is the most common primary intraocular tumor. Activating 
mutations in GNAQ and GNA11, which encode members of the q class of the G-protein 
alpha subunit (Gq), are the primary drivers of uveal melanoma tumorigenesis. I show  
iv 
that oncogenic GNAQ forms a complex with GEP100 to activate ARF6, which in turn 
induces all known GNAQ-mediated signaling pathways as well as the relocalization of  
-catenin from the cell surface to the nucleus. These findings indicate that ARF6 is the 
primary immediate effector of an oncogenic GNAQ/GEP100 complex that regulates 
multiple signaling pathways shown to be important in the control of uveal melanoma 
tumorigenesis and growth. These results not only provide an improved understanding of 
the molecular mechanism underlying Gq-mediated tumorigenesis but also suggest a 
new target for therapeutic intervention in uveal melanoma. 
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The Role of WNT5A in Inducing Canonical WNT Signaling in Melanoma 
Canonical WNT signaling has been largely attributed to the stabilization of the 
cytoplasmic pool of -catenin, leading to nuclear translocation and activation of 
transcription
1
. In addition to transcription, -catenin has a distinct structural role at the 
plasma membrane in stabilizing adherens junctions (AJs) and cell-cell contacts by linking 
cadherins to the actin cytoskeleton
2
. Although adhesion and transcription share the same 
intracellular pool of -catenin, the mechanism that controls -catenin movement between 
intracellular compartments
3
 and how junctional -catenin might contribute to canonical 
signaling is unknown. The release of -catenin from cadherin potentially has dual roles in 
promoting tumor cell invasion. First, it weakens cell-cell contacts by destabilizing AJs, 
thus allowing cells to move more freely. Second, by increasing the pool of free 
cytoplasmic -catenin, more -catenin is available for translocation into the nucleus 
where it can promote transcription of genes involved in invasion and metastasis
2,3
. 
Although WNT5A has emerged as a key mediator of tumor cell invasion, its role 
in invasion has primarily been attributed to -catenin-independent (noncanonical) 
signaling
4
. Several studies have demonstrated that WNT5A can stimulate canonical  
 2 
signaling in Xenopus and in mammalian cells
5-10
. It has been shown that WNT5A induces 
-catenin transactivation when the WNT receptor Frizzled 4 (FZD4) and its coreceptor 
LRP5 are overexpressed in HEK293T cells
10
, which suggests that WNT5A can activate 
canonical WNT signaling depending on receptor context. However, it is unknown 
whether this occurs in an endogenous mammalian system or in the setting of cancer. 
Previously, it has been shown that the WNT/β-catenin signaling pathway is 
necessary for melanocyte development
11
 and that nuclear β-catenin promotes the 
proliferation and growth of melanoma cells through interactions with certain transcription 
factors
12
. However, the function of β-catenin in melanoma metastasis remains 
controversial. Some studies suggest that -catenin suppresses invasion of melanoma 
cells
13
, and the loss of -catenin is correlated with a poor survival rate in melanoma 
patients
14,15
. However, other studies have shown that ectopic expression of wild type or 
stabilized -catenin promotes melanoma invasion and metastasis16-18. Because melanoma 
is a heterogeneous disease, -catenin function may be variable between cell lines and 
model systems. During the process of melanoma progression, tumor cells may need to 
switch between a proliferative versus invasive phenotype. Although the function of -
catenin during progression is unclear, it has been shown that the expression of LEF1 or 
TCF4, which are transcription factors that bind -catenin to activate transcription, 
determined the proliferative or invasive phenotypes of melanoma cells
19
. In this study, we 
have found that nuclear -catenin promotes invasion in the subpopulation of melanoma 
cells expressing WNT5A. Noncanonical WNT5A signaling is clearly important, but our 
data indicate that -catenin signaling is also active downstream of WNT5A. 
 
 3 
GPCR/Gq Signaling in Cancer 
The stimulation of G-protein-coupled receptors (GPCRs) by various extracellular 
signals induces several different intracellular signaling pathways that control many 
cellular biological functions. Ligand-induced stimulation of GPCRs causes a 
conformational change in the receptor, which stimulates it to act as a guanine nucleotide 
exchange factor (GEF) activity to activate heterotrimeric G-protein complexes consisting 
of G, G, and G subunits. The GEF activity of GPCRs induce the exchange of a GDP 
for a GTP on G subunits, causing a dissolution of the heterotrimeric G-protein complex 




Emerging experimental results and intensive genomic approaches have identified 
activating mutations in GPCRs and G proteins in multiple human cancers
22
. For example, 
genomic analyses of many human cancers have recently identified a high frequency of 
activating somatic mutations in Gα subunits. The frequency of GNAS (encoding Gαs), 
GNAQ (encoding Gαq), and GNA11 (encoding Gα11) mutations is approximately 4.5%, 
3.4%, and 2.5%, respectively, over all tumor types. The mutation hotspots are R201 or 
Q227 for GNAS and Q209 or R183 for GNAQ/GNA11. These mutations result in 
constitutively active Gα-mediated signaling by reducing the rate of GTP hydrolysis of the 
active GTP-bound Gα subunits22. These activating Gα mutations have thus far proved 
challenging for direct pharmacologic inhibition. Instead, most studies have focused on 
potential downstream therapeutic targets such as protein kinase C (PKC), a downstream 
component of GNAQ/GNA11 signaling
24,25
. Phospholipase C (PLC) cleaves 
phosphatidylinositol (4,5)-bisphosphate (PIP2) to produce diacylglycerol (DAG) and 
 4 
inositol triphosphate (IP3), which then activate PKC-MAPK signaling
26
. A previous 
study showed that the combined inhibition of PKC and MAPK signaling reduces the 
proliferation of tumor cells and tumorigenesis in uveal melanoma xenograft models
25
. 
Moreover, the small GTPase proteins, RhoA and Rac1, have been also shown to be 
downstream components of oncogenic GNAQ/GNA11. Activation of RhoA and Rac1 by 
GNAQ initiates the activation of multiple MAPKs such as ERK, p38, and JNK, all of 
which regulate the activity of AP-1 transcriptional factors
27
. Recently, it has been 
demonstrated that oncogenic GNAQ-mediated activation of RhoA and Rac1 also 
promotes the translocation of YAP to the nucleus where it can associate with TEAD and 
promote transcription
28
. Although these findings identify promising candidates for 
therapeutic targeting, it would be unlikely to achieve complete inhibition of 
GNAQ/GNA11 oncogenic signaling by targeting each of these downstream targets 
individually. A similar situation occurs in RAS signaling. Somatic activating mutations in 
RAS are the most common mutations in human cancers. Although much effort has been 
expended to understand and inhibit the downstream components of oncogenic RAS, there 




Uveal melanoma is the most common ocular malignancy and there is currently no 
effective treatment for metastatic uveal melanoma largely because of the lack of an 
understanding of the molecular mechanisms underlying this cancer
30
. However, several 
recent major advances have been made in elucidating the signaling pathways that control 
uveal melanoma oncogenesis. Mutations in one of two different G subunits (GNAQ and 
GNA11) are found in over 80% of uveal melanomas
31,32
. Although it has been 
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demonstrated that activating mutations in GNAQ/GNA11 trigger multiple downstream 
effectors and pathways including PLC/PKC, ERK, p38, JNK, and YAP and that 
inhibition of any one of these downstream effectors reduces tumorigenesis in uveal 
melanoma xenograft models
24,25,27,28,33
, the molecular mechanisms by which these 
activating G mutations orchestrate all of these signaling pathways remain unknown. 
 
The Role of ARF Proteins in Endocytosis, Cytoskeletal Remodeling, 
and Cancer 
ARF proteins are part of the Ras-superfamily of GTPases and mainly control 
membrane trafficking and cytoskeletal remodeling. In mammals, the ARF superfamily 
includes six ARF proteins and several ARF-like proteins. ARF proteins can be placed 
into three classes by their structural similarities: class I (ARF1-3), class II (ARF4 and 5), 
and class III (ARF6). It has been shown that ARF1 functions to regulate membrane 
trafficking at multiple intracellular sites. ARF6 is also involved in membrane trafficking 
and remodeling and functions mainly in membrane endocytosis and recycling at the cell 
periphery through its GTPase activity
34-36
. 
ARF6 Q67L is a constitutively active form of the protein due to its defect in GTP 
hydrolysis. It is primarily localized to invagination pits at plasma membrane or 
intracellular vacuoles and plays a role in blocking the endocytosis of several cell surface 
molecules. ARF6 T27N, which acts as a dominant negative due to its inability to bind 
guanine nucleotides, mainly localizes to intracellular tubulovesicular (TV) structures and 
can block cell surface molecules from recycling back to the cell surface. The endogenous 




. Therefore, it has been suggested that ARF6 GTPase activity 
controls the direction of membrane trafficking to regulate cell motility
40
. However, ARF6 
may have different functions in different cellular contexts. The expression of ARF6 is 
ubiquitous and has been shown to function in a variety of biological events, including 
actin cytoskeletal remodeling and activation of phosphatidylinositol 5-kinase
35,41
. In 
endothelial cells, it has been shown that the SLIT-ROBO ligand-receptor system induces 
GTPase activating proteins (GAPs) to convert ARF6 to the inactive, GDP-bound state, 
enhancing VE-cadherin localization to the cell surface and promoting stability of cell-cell 
interactions
42,43
. In epithelial cells, ARF6 activated by hepatocyte growth factor (HGF) 
promotes internalization of E-cadherin and cell motility
44
. In breast cancer cells, the 
epidermal growth factor receptor (EGFR) activates ARF6 through GEP100, thus 
reducing E-cadherin at the cell surface and promoting an invasive phenotype
45
. 
Therefore, ARF6 is thought to be at the center of multiple signals that influence cellular 
motility by regulating AJs. ARF6 was initially found as a cofactor necessary for the 
cholera toxin-catalyzed ADP ribosylation of the Gαs subunit
46
. Several studies have 
demonstrated that ARF6 both regulates the internalization of GPCRs and is itself 
activated by G proteins following GPCR stimulation or through activating G 
mutations
47-51
. However, it is unknown whether ARF6 is necessary for the G protein-
mediated signaling pathways that control multiple cellular biological functions. 
 
Summary 
In this dissertation, I show that ARF6 acts as a molecular switch to control the 
shuttling of -catenin between the plasma membrane and the cytoplasm in cutaneous 
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melanoma. This switch is controlled by two competing signals, WNT5A and SLIT2. 
WNT5A activates ARF6, leading to the release of -catenin from N-cadherin, 
accumulation of cytoplasmic and nuclear -catenin, increased transcription, and tumor 
cell invasion. In contrast, SLIT2 inactivates ARF6, thus stabilizing the interaction 
between N-cadherin and -catenin and reducing transcription and invasion. These results 
indicate that WNT5A can induce the disruption of cadherin-catenin interactions and 
WNT5A signaling contributes to canonical WNT/-catenin signaling via ARF6.  
In uveal melanoma, I demonstrate that ARF6 is both necessary and sufficient for 
oncogenic GNAQ signaling and that ARF6 acts an immediate downstream effector of a 
GNAQ/GEP100 complex by orchestrating multiple signaling pathways, including 
PLC/PKC, Rac/Rho, ERK/p38/JNK, YAP, and -catenin. ARF6 controls these signaling 
pathways by regulating the intracellular trafficking of oncogenic GNAQ. Therefore, this 
work describes an upstream protein complex that controls all of the previously known 
GNAQ-mediated oncogenic pathways as well as the newly identified -catenin signaling 
pathway. These results provide a new mechanistic framework for studying other cancers 
harboring activating G protein mutations and suggest a possible therapeutic approach 
for inhibiting multiple oncogenic pathways by targeting a single immediate effector of 
activated GNAQ that lies upstream of all the known oncogenic pathways. 
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CHAPTER 3  
 
ARF6 IS AN ACTIONABLE NODE THAT ORCHESTRATES ONCOGENIC GNAQ 
SIGNALING IN UVEAL MELANOMA 
 
Summary 
Activating mutations in Gq proteins, which form the  subunit of certain 
heterotrimeric G proteins, drive uveal melanoma oncogenesis by triggering multiple 
downstream signaling pathways, including PLC/PKC, Rho/Rac, and YAP. Here we show 
that the small GTPase ARF6 acts as a proximal node of oncogenic Gq signaling to 
induce all of these downstream pathways as well as -catenin signaling. ARF6 activates 
these diverse pathways through a common mechanism - the trafficking of GNAQ and -
catenin from the plasma membrane to cytoplasmic vesicles and the nucleus, respectively. 
Blocking ARF6 with a novel small molecule reduces uveal melanoma cell proliferation 
and tumorigenesis in a mouse model, confirming the functional relevance of this pathway 
and suggesting a new therapeutic strategy for G-mediated diseases. 
 
Introduction 
Mutations that confer constitutive activity to G protein-coupled receptors 






, and Sturge-Weber syndrome
6,7
. One such 
disease is uveal melanoma in which over 80% of tumors harbor an oncogenic activating 
mutation in either of two G q class (Gq) proteins: GNAQ and GNA118,9. 
Uveal melanoma is the most common primary ocular malignancy and there are no 
effective treatments for metastatic forms of this disease. The discovery of oncogenic 
GNAQ and GNA11 mutations in uveal melanoma has led to the identification of multiple 
downstream signaling pathways that could be targeted for therapeutic purposes
10
. These 
signaling pathways include phospholipase C- (PLC-)/protein kinase C (PKC) and 
Rac1/RhoA, which lead to the activation of ERK, p38, JNK, and YAP and subsequent 
AP-1- and YAP/TEAD-mediated transcription
11-15
. However, it has been unclear how 
activating mutations in Gq proteins exert their control over these divergent downstream 
pathways and whether activated Gq proteins govern additional oncogenic pathways. 
The small GTPase ADP-ribosylation factor 6 (ARF6)
16
 is an attractive candidate 
for being an effector of Gq signaling. ARF6 is activated by a variety of different ARF-
guanine nucleotide exchange factors (ARF-GEFs), depending on the stimulating factor or 
cell type. Heterologous expression studies in HEK293T cells have suggested that 
activated Gq proteins associate with various ARF-GEFs and ARF6, which leads to the 
activation of ARF6
17,18
. Other studies have shown the crucial role ARF6 plays in 
invasion, metastasis, and proliferation of several different types of cancers
19-24
. ARF6 is a 
critical mediator of endocytosis and the recycling of multiple membrane receptors, 
including GPCRs and cadherin-catenin complexes
25-28
. We recently demonstrated that in 
human cutaneous melanoma cells, WNT5A-stimulation of the GPCR FZD4 activates 
 49 
ARF6, which promotes the trafficking of -catenin from its N-cadherin-bound membrane 
form to the nucleus where it stimulates TCF-mediated transcription
19
. 
Here, we show that oncogenic GNAQ interacts with the ARF-GEF GEP100 to 
activate ARF6, which then functions as an immediate downstream effector to increase 
PLC/PKC, Rac1/RhoA, ERK/p38/JNK, YAP, and -catenin signaling. Importantly, the 
ARF6-mediated increase in Gq signaling is correlated with the trafficking of GNAQ 
from the plasma membrane to cytoplasmic vesicles, suggesting that the intracellular 
location of mutant Gq proteins may play an important role in oncogenic signaling. 
Consistent with a nodal signaling role for ARF6, blocking ARF6 activation reduces 
tumor establishment and growth in a xenograft model of uveal melanoma. These results 
provide a mechanistic framework for studying other cancers harboring activating G 
protein mutations and suggest that targeting a single immediate effector of Gq offers a 
new therapeutic approach for inhibiting multiple oncogenic pathways.  
 
Results 
We investigated whether ARF6 might also be important in cancers harboring 
somatic activating mutations of Gq subunits based on the reported role of ARF6 in 
several cancers
19-24
 and studies showing that Gq proteins can activate or signal through 
ARF6
17,18,29
. We first examined ARF6 protein levels in human uveal melanomas, known 
to often carry activating mutations of GNAQ or GNA11. ARF6 protein levels were 
approximately 3-fold higher in uveal melanomas than in non-tumor ocular tissues (Figure 
3.1a). We next tested whether GNAQ in Mel92.1 and Mel202 uveal melanoma cells was 
required for ARF6 activation. Mel202 and Mel92.1 cells carry GNAQ
Q209L
, the most 
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common activating mutation in GNAQ
8
. The levels of ARF6-GTP were measured 
following GNAQ knockdown using two different siRNAs. Each knockdown reduced 
ARF-GTP levels by greater than 50% compared to a negative control siRNA that lacks 
homology to any known mammalian gene (Figure 3.1b). Consistent with these results, 
HEK293T cells transfected with vectors expressing GNAQ
Q209L
 exhibited elevated levels 
of ARF6-GTP whereas those cells expressing wild type GNAQ did not (Supplementary 
Figure 3.1). Interestingly, uveal melanoma cells that carry GNAQ mutations do not 
express WNT5A, while tumor cells that possess wild type GNAQ and GNA11 express 
high levels of WNT5A, which is necessary for ARF6 activation in those cells 
(Supplementary Figure 3.2). Knockdown of GNAQ in cultured uveal melanoma cells has 
been shown to inhibit cell growth
8
. To determine if this inhibition is ARF6 dependent, we 
compared growth parameters between uveal melanoma cells transfected with siRNAs 
directed against ARF6 or GNAQ. Knockdown of ARF6 or GNAQ in both Mel92.1 and 
Mel202 cells caused similar reductions in cell proliferation and anchorage-independent 
colony growth (Figure 3.1c and 3.1d). These results demonstrate a central role for ARF6 
in oncogenic GNAQ-mediated cell proliferation. 
Signaling pathways stimulated by oncogenic GNAQ include those mediated by 
PLC-PKC and Rac/Rho
11,13,14,30
. Knockdown of either ARF6 or GNAQ in uveal 
melanoma cells resulted in a significant reduction in PLC activity ranging from 24% to 
80% inhibition when using a phosphoinositide turnover assay (Figure 3.2a). Consistent 
with this reduction in PLC activity, the level of phosphorylated myristoylated alanine-
rich C kinase substrate (p-MARCKS), a substrate of PKC, was decreased by ARF6 
knockdown (Figure 3.2b and Supplementary Figure 3.3a). Knockdown of ARF6 or 
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GNAQ also significantly reduced the levels of Rac1-GTP/RhoA-GTP and their 
downstream readouts, phosphorylated ERK, p38, JNK, and c-jun (Figures 3.2c-3.2e and 
Supplementary Figures 3.3b-3.3g). The reduction of c-jun phosphorylation resulted in 
decreased AP-1 transcriptional activity (Figure 3.2f). 
Oncogenic GNAQ enhances nuclear YAP activation through Rac1/RhoA, 
implicating YAP as a potential therapeutic target for uveal melanoma
13,14
. Blocking 
ARF6 or GNAQ inhibited by 60% the nuclear localization of YAP in uveal melanoma 
cells, as detected by immunocytofluorescence and subcellular 
fractionation/immunoblotting (Figures 3.2g, 3.2h, and Supplementary Figure 3.3h). 
mRNA levels of the YAP target genes CYR61 and CTGF were also reduced in Mel92.1 
and Mel202 cells in which ARF6 was knocked down (Figure 3.2i). 
The finding that ARF6 is an effector of oncogenic GNAQ that activates multiple 
signaling pathways suggested that constitutively active ARF6 (ARF6
Q67L
) would also 




 in HEK293T 
cells induced the PLC-PKC and Rac1/RhoA-MAPK pathways, including the activation 
of ERK, p38, JNK, and c-jun and the increase in AP-1 transcriptional activity, YAP 
nuclear accumulation, and YAP-mediated transcription (Supplementary Figures 3.4b-
3.4f). These results show that ARF6 is both necessary and sufficient to mediate 
oncogenic GNAQ activity and thus serves as a critical signaling node. 
Activating mutations in -catenin are found in many human cancers31. Our 
previous work showed that in a model of cutaneous melanoma, WNT5A-activated ARF6 
promotes the relocalization of -catenin from the membrane to the nucleus to induce -
catenin-mediated transcription and cancer cell invasion and metastasis
19
. We therefore 
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examined whether the oncogenic GNAQ-activated ARF6 also increased the translocation 
of -catenin from the membrane to the nucleus in uveal melanoma cells. Knocking down 
GNAQ or ARF6 in uveal melanoma cells resulted in an increase in the membrane pool of 
-catenin and a corresponding decrease in the cytosolic and nuclear pools, as shown by 
both immunocytofluorescence and subcellular fractionation analyses (Figures 3.3a and 
3.3b). These treatments also significantly reduced luciferase activity in a 7TFP-mediated 
luciferase reporter assay (a measure of -catenin-mediated transcription) (Figure 3.3c). 
Knockdown of GNAQ and ARF6 did not alter total -catenin protein levels 
(Supplementary Figure 3.5a), suggesting that the mechanism that controls -catenin 
intracellular localization by GNAQ
Q209L
-activated ARF6 is independent of the 





 decreased the membrane pool of -catenin and concomitantly 
increased the cytosolic and nuclear pools of -catenin (Supplementary Figure 3.5b). 
These same active forms of ARF6 or GNAQ also increased the activity of a -catenin 
responsive luciferase reporter (Supplementary Figure 3.5c). Together, these results 
provide the first demonstration that an oncogenic Gq protein induces -catenin 
signaling and that it does so through the activation of its effector ARF6, which promotes 
the relocalization of -catenin from the plasma membrane to the nucleus. 
-catenin signaling can increase cell proliferation in some cancer cells31,32. To 
determine whether -catenin signaling in uveal melanoma cells influences cell 
proliferation, we exposed Mel92.1 and Mel202 cells to two different inhibitors of -
catenin signaling XAV-939 and IWR-1-endo
33,34
. After 72 hours of treatment, both 
XAV939 and IWR-1-endo inhibited cell proliferation in a concentration-dependent 
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manner with a GI50 (50% growth inhibition) of around 3 µM and 10 µM, respectively, in 
both cell lines (Supplementary Figure 3.5d). These results suggest that GNAQ
Q209L
-
ARF6-mediated -catenin signaling plays a role in uveal melanoma cell proliferation. 
We next sought to identify the ARF-GEF responsible for oncogenic GNAQ-
mediated ARF6 activation. Both ARNO and GEP100 are known ARF6-GEFs in 
endothelial cells and in multiple cancer cells
19,21,23,35
, and both ARF-GEFs are expressed 
in human uveal melanoma tissues (Supplementary Figure 3.6a). Knockdown of GEP100 
(Supplementary Figure 3.6c), but not ARNO (Supplementary Figure 3.6b), reduced 
ARF6-GTP levels by 60% in uveal melanoma cells. Knockdown of GEP100 resulted in 
50% inhibition of cell proliferation and 80% inhibition in anchorage-independent colony 
growth (Supplementary Figures 3.6d and 3.6e), mimicking the cellular phenotypes of 
ARF6 knockdown. Similar to the silencing of ARF6 and GNAQ, knockdown of GEP100 
also inhibited PLC-PKC, Rac1/RhoA, MAPK, YAP, and -catenin signaling, as 
evidenced by decreased activation of the downstream effectors and reduced nuclear 
localization and transcriptional activity of YAP and -catenin (Supplementary Figures 
3.7 and 3.8). We hypothesized that oncogenic GNAQ and GEP100 might form a complex 
that activates ARF6 in uveal melanoma cells, because such complexes have been shown 
to occur following ectopic expression of Gq and GEP100 in HEK293T cells17,18. 
Immunoprecipitation of oncogenic GNAQ
Q209L
 from uveal melanoma cells co-




ARF6 has a known role in endocytosis of GPCRs
25,27
, and GPCRs and G 




examine whether ARF6 might control activated GNAQ signaling through a similar 
protein trafficking mechanism, we knocked down ARF6 in Mel92.1 and Mel202 cells and 
assessed intracellular localization of GNAQ
Q209L
 using both immunocytofluorescence and 
cell fractionation analysis. Upon ARF6 silencing, there was an increase in GNAQ
Q209L
 
localized to the plasma membrane with a concomitant reduction of GNAQ
Q209L
 in the 
cytosol and cytoplasmic vesicles (Figure 3.4). GEP100 knockdown likewise exhibited a 
shift of GNAQ
Q209L
 localization from the cytosol and cytoplasmic vesicles to the plasma 
membrane (Supplementary Figure 3.9). These results suggest that activated ARF6 directs 
GNAQ
Q209L
 to the cytoplasmic vesicles leading to an increase in signaling of downstream 
oncogenic pathways. 
Our finding that ARF6 acts as an immediate downstream effector of GNAQ
Q209L
 
that controls all of the currently recognized signaling pathways governed by oncogenic 
Gq compelled us to investigate whether chemical inhibitors of ARF6 activation might 
provide an effective pharmacologic treatment of uveal melanoma. To our knowledge, no 
direct inhibitors of ARF6 have been published or are commercially available. Therefore, 
ARF-GEF inhibitors, such as SecinH3, have been used as surrogates for ARF6 inhibition 
in past studies
19,43
. However, ARNO, a target for SecinH3 inhibition, promotes epidermal 
growth factor receptor activation independent of its ARF-GEF activity
44
, so inhibiting 
ARF-GEFs rather than ARF6 directly could lead to off-target effects. Therefore, it is 
imperative to find direct ARF6 inhibitors that can reduce these unintended consequences. 
To identify such inhibitors, a high throughput screen (HTS) based on a fluorometric 
biochemical assay was devised to identify chemically tractable, reversible, allosteric 
inhibitors that target ARF6 directly (Figure 3.5a and Supplementary Figures 3.10a-
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3.10c). The requirement for an allosteric, non-nucleotide-competitive mode of action was 
dictated by intracellular concentrations of GTP, which are approximately 100 µM. A 
comparative evaluation of more than 20 chemical series and singleton HTS hits from the 
DiverSet collection
45
 of approximately 50,000 compounds (ChemBridge) identified the 
pyrazolopyrimidinone compound NAV-2729 (Figure 3.5b and Supplementary Figures 
3.11) as the most promising ARF6 chemical probe candidate. This compound was 
selected for further evaluation based on the following properties: i) low micromolar 
potency with IC50 values of 1.0 µM and 3.4 µM determined using fluorometric and 
orthogonal radiometric ARF6 nucleotide exchange assays, respectively (Figure 3.5c); ii) 
direct inhibition of ARF6 as evidenced by nearly equipotent inhibitory effects towards 
spontaneous and ARF-GEF-catalyzed ARF6 nucleotide exchange (Figure 3.5d); iii) a 
non-nucleotide competitive mechanism supported by the observation that GTP does not 
affect the ability of the inhibitor to stimulate release of a fluorogenic nucleotide from its 
complex with ARF6 (Figure 3.5e and Supplementary Figure 3.10d); iv) high selectivity 
as evidenced by the lack of inhibitory effects for other small GTPases such as RhoA, 
Rac1, H-Ras, and Cdc42 at concentrations up to 50 µM (Supplementary Figures 3.10e-
3.10h); v) reversible inhibition (Figure 3.5f); and vi) overall chemical tractability 




The proposed direct inhibitory mechanism of NAV-2729 agrees well with the 
results of molecular docking studies using a structural homology model of the 
ARF6/ARF-GEF complex (Figure 3.5g). The model predicts association of NAV-2729 
with ARF6 in its GEF-binding area, which does not overlap with the nucleotide-binding 
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pocket. A hydrogen bond between the inhibitor carbonyl group and -amino group of 
ARF6 Lys58 residue, as well as the interaction of its nitrophenyl moiety with a 
hydrophobic pocket formed by aromatic side chains of ARF6 residues Phe47, Trp62, 
Trp74, and Tyr77 make major contributions to the inhibitor binding energy 
(Supplementary Figure 3.10i). Most importantly, NAV-2729 exhibited a spectrum of 
biological activities in uveal melanoma cells that are predicted for an ARF6 inhibitor. 
Treatment of Mel92.1 and Mel202 cells with NAV-2729 inhibited ARF6 activation 
(Figure 3.5h) and mimicked ARF6 and GEP100 knockdown by driving GNAQ from the 
cytoplasmic vesicles to the plasma membrane (Figures 3.5i and 3.5j) and reducing 
anchorage-independent colony growth (Figure 3.5k). 
The finding that the activation state of ARF6 regulates multiple oncogenic GNAQ 
signaling pathways by controlling the intracellular localization of GNAQ
Q209L
 suggested 
that ARF6 may be a viable therapeutic target for GNAQ-mediated tumorigenesis. We 
tested this hypothesis in an orthotopic xenograft mouse model of uveal melanoma. Stable 
uveal melanoma cells expressing either short hairpin RNAs (shRNA) directed against 
ARF6 or a nonspecific control sequence were generated by lentiviral infection of Mel202 
cells. These cells were injected into the posterior vitreous chamber of the eyes of 
immunocompromised nude mice. Tumor incidence and size were markedly decreased in 
mice injected with Mel202 cells expressing ARF6 shRNA compared to mice injected 
with cell expressing control shRNA (Figures 3.6a and 3.6b). Systemic treatment by 
intraperitoneal injection of the direct ARF6 inhibitor NAV-2729 also significantly 
reduced uveal melanoma tumor establishment and growth in an orthotopic xenograft 
mouse model (Figures 3.6c and 3.6d). No gross signs of toxicity were seen in these 
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studies or in other studies in which the drug was used at these same concentrations. 
Collectively, these results suggest that the pharmacological inhibition of ARF6 may 
represent an effective therapeutic approach to the treatment of uveal melanoma and 
possibly other cancers driven by activating G mutations. 
 
Discussion 
Activated oncogenes such as G proteins or members of the RAS superfamily of 
GTPases act through central signaling nodes that subsequently trigger multiple molecular 
events that together induce cancer initiation and invasion
4,47
. Previous studies have shown 
that activating mutations in the Gq proteins GNAQ or GNA11 promote PLC/PCK and 
Rac/Rho signaling, leading to both the activation of ERK, p38, JNK, and YAP and 
subsequent AP-1- and YAP/TEAD-mediated transcription
11-14
. In the present study, we 
have expanded the number of signaling pathways that are known to be regulated by an 
activated Gq protein to include an ARF6--catenin pathway in which activated ARF6 
promotes the release and subsequent translocation of membrane-bound -catenin to the 
nucleus where it induces transcription. To our knowledge, this is the first report that -
catenin trafficking can be controlled by an activated Gq protein. By employing 
biochemical and cellular assays and a newly identified small molecule inhibitor, we also 
show that a GNAQ
Q209L
-GEP100 complex activates ARF6, which functions as an 
immediate downstream effector to induce the PLC/PKC and Rho/Rac signaling pathways 
that lead to AP-1 and YAP/TEAD-mediated transcription (Figure 3.6e). Thus, the 
activation of ARF6 controls all of the currently known oncogenic pathways mediated by 
Gq activating mutations. 
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Our data suggest that activated ARF6 controls GQ and -catenin signaling by 
regulating protein trafficking between intracellular compartments. Oncogenic GNAQ 
forms a protein complex with GEP100, which activates ARF6 to promote the 
redistribution of cell surface GNAQ to cytoplasmic vesicles. GNAQ signaling appears to 
primarily occur in these vesicles, because knockdown of ARF6 or GEP100 or chemical 
inhibition of ARF6 induces the relocalization of GNAQ from the cytoplasm to the plasma 
membrane with a concomitant decrease in signaling of all GNAQ-mediated pathways. 
Although signaling from G proteins such as G and RAS proteins have traditionally been 
thought to occur only at the plasma membrane, more recent studies have challenged this 
view, suggesting that signaling can also derive from cytoplasmic vesicles
36-42,48-51
. Our 
data agree with these recent studies but unexpectedly suggest that most of the signaling 
from active GNAQ in uveal melanoma emanates from cytoplasmic vesicles rather than 
the plasma membrane. These results, coupled with previous work suggesting that 
maximal oncogenic H-RAS signaling requires endocytosis and endocytic recycling
52
, 
suggest that the intracellular location of an oncogene may determine its level of activity 
and that blocking the trafficking of an oncogene to its primary signaling center may 
effectively diminish its activity. In the case of GNAQ and H-RAS, the primary signaling 
center appears to be in cytoplasmic vesicles. The activation of ARF6 by oncogenic 
GNAQ also leads to the release of -catenin from the plasma membrane and its 
subsequent transportation to the nucleus where it induces gene transcription and helps to 
promote uveal melanoma cell proliferation. This result is consistent with our previous 
study in cutaneous melanoma, which demonstrated a similar relocalization of -catenin 
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and increased -catenin-mediated transcription following stimulation of the FZD4/LRP6 
co-receptor complex with WNT5A
19
. 
Our discovery that ARF6 is an immediate downstream effector of the 
GNAQ
Q209L
-GEP100 complex suggests that targeting ARF6 with a single small molecule 
may inhibit all of the currently known Gq-mediated oncogenic signaling pathways. The 
necessity and sufficiency of ARF6 activation in orchestrating activated Gq oncogenic 
signaling also reveals a strategy to blunt cancer initiation and progression, not just tumor 
invasion and metastasis. We provide evidence that ARF6 is an actionable node suitable 
for further development as a therapeutic target by identifying a novel, direct inhibitor of 
ARF6 that reduces tumor establishment and growth in a xenograft model of uveal 
melanoma. 
Uveal melanoma is a devastating cancer and serves as the prototype for activated 
G protein-mediated cancers. Current treatment relies on surgery and radiation for 
localized disease, but there is no effective systemic therapy for advanced disease
53
. The 
identification of ARF6 as a signaling partner of GNAQ offers a target for new treatment 
regimens that has implications extending beyond Gq proteins and uveal melanoma to 
other cancers harboring activated G oncogenes, such as pancreatic and biliary 
cancers
3
. Directly targeting certain oncogenes, e.g., activated RAS GTPase, has been 
challenging
54,55
, although recent advances have been made
56,57
. Approaches that 
individually inhibit each arm of an activated oncogenic pathway have been adopted but 
are inefficient, spurring interest in combination trials as an alternate approach
58
. By 
illuminating how a specific activated G oncogene orchestrates multiple divergent 
downstream signaling arms through a single effector, our work suggests that targeting 
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such primary nodal points in the signaling pathways of other GTPases could provide an 
effective method for combatting oncogenesis and tumor establishment. 
 
Materials and Methods 
Cell lines, proliferation assay, and anchorage-independent  
colony growth 
Uveal melanoma cells were maintained in RPMI 1640 supplemented with 10% 
fetal bovine serum (FBS). LOX and HEK293T cells were purchased from ATCC and 
maintained in DMEM supplemented with 10% FBS. Cell proliferation assays were 
performed using CyQUANT (Invitrogen) according to the manufacturer’s instructions. 
5 × 103 uveal melanoma cells were plated into each of three or four wells of a 96-well 
plate and fluorescence was measured 4 h later after cell attachment to obtain baseline 
measurements and at 72 h as endpoint measurements. Anchorage-independent colony 
growth was quantified by the CytoSelect 96-Well Cell Transformation Assay (Cell 
Biolabs) as per manufacturer’s instructions. After 12-15 days, relative colony 
size/number was confirmed by microscopic examination and measured by adding 
CyQUANT reagent to the cultures and measuring fluorescence using a plate reader at 
excitation/emission wavelengths of 485/530 nm. 
RNA interference, plasmids, transfections, lentiviral transduction,  
qRT-PCR, and chemicals 
siRNA duplexes (20 nmol) were transfected into uveal melanoma cells using 
Lipofectamine RNAiMAX (Invitrogen). Plasmids for wild type GNAQ and GNAQ
Q209L
 
were obtained from Missouri S&T cDNA Resource Center. The coding regions of both 
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constructs were re-cloned into pcDNA3.1 vector for MYC epitope-tagging at the N-
terminal. For ectopic expression in HEK293T, cells were seeded in 10-cm plates and 
transfected with the respective plasmids using Lipofectamine LTX (Invitrogen). 
Lentiviruses containing control and ARF6 shRNA expression constructs were purchased 
from Sigma and were used to infect Mel202 uveal melanoma cells. Infected cells were 
selected using 1 µg/ml of puromycin (Invitrogen) for 5 days. qRT-PCR was performed 
with the Applied Biosystems 7900HT and QuantiTect SYBR Green PCR kit (Qiagen) 
with the primers listed in Table S1. IWR-1-endo and XAV-939 were purchased from 
Calbiochem. 
ARF6/RhoA/Rac1 pull-downs, immunoblots, immunoprecipitation,  
cell fractionation, PLC assay, luciferase assay,  
and immunocytofluorescence staining 
ARF6-GTP pull-downs were performed with Arf6 Activation Assay Kit (Cell 
Biolabs) and RhoA/Rac1-GTP pull-downs were prepared with Rac1 Activation Assay 
Kit/RhoA Activation Assay Kit (Millipore) according to the manufacturer’s instructions. 
For immunoblotting and immunoprecipitation, cell lysates were prepared in 25 
mM HEPES (pH 7.5), 150 mM NaCl, 1% NP-40, 10 mM MgCl2, 1 mM EDTA, and 2% 
glycerol, plus phosphatase and protease inhibitors. Immunoprecipitation was performed 
as previously described
19
. For immunoblotting, primary antibodies were diluted in 5% 
NFDM or 5% BSA in PBS or TBS plus 0.1% Tween 20 and incubated overnight at 4°C. 
Plasma membrane or total membrane fraction was isolated with Plasma Membrane 
Protein Extraction Kit (Abcam) and cytosolic/nuclear fractions were prepared with NE-
PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific) according to the 
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manufacturer’s instructions. Antibodies against ARF6 (Millipore), GNAQ (Abcam), 
GEP100 (Sigma), ARNO (Abnova), -tubulin, MYC (Santa Cruz Biotechnology), Rac1, 
-catenin (BD Biosciences), -actin, GAPDH, HA, RhoA, MARCKS, p-MARCKS, ERK, 
p-ERK, p38, p-p38, JNK, p-JNK, c-jun, p-c-jun, YAP, Na K-ATPase, and Lamin A/C 
(Cell Signaling Technology) were used for immunoblotting and/or immunoprecipitation. 
Quantification for all immunoblots was by scanning densitometry whereby changes were 
normalized to loading control, input, and/or total particular protein level, and represents 
an amalgamation of all independent experimental replicates. Geometric means and 95% 
confidence intervals were calculated to determine statistically significant changes in 
protein levels. 
-catenin- and AP-1-mediated transcriptional activities in uveal melanoma cells 
were assayed using lentivirally transduced cells that stably express the TOPflash-based 
7TFP luciferase reporter (Addgene)
59
 or AP-1 luciferase reporter (Qiagen). 20-40 µg of 
cell lysates were assayed for firefly luciferase with the Luciferase Assay System 
(Promega).  Luciferase assays for -catenin, AP-1, and YAP in HEK293T were 
performed following the transfection of TOPflash, AP-1, or TEAD4 firefly luciferase 
reporter plasmids (Addgene) and renilla plasmid for a normalized control. Dual 
luciferases were detected with Dual-Luciferase Reporter Assay System (Promega) 
according to the manufacturer’s instructions. 
PLC activity was determined using phosphoinositide turnover assay as previously 
described
11
. Briefly, 1 ×  106 siRNA-transfected Mel92.1 and Mel202 uveal melanoma 
cells were seeded into each well of a 6-well plate and 2 × 105 HEK293T cells ectopically 
expressing specific genes following plasmid transfection were plated on each well of a 
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24-well plate. Cells were incubated with 3 µCi or 1 µCi/well of myo-[
3
H]-inositol (Perkin 
Elmer) for 24 h. 10 mM LiCl was added for 20 min to stop the phosphoinositide turnover. 
5% TCA was used for cell lysis and the supernatants were applied to an anion-exchange 
column (Bio-Rad, AG1-X8). Radioactivity in eluted samples was determined with a 
Beckman scintillation counter. 
3 × 10
6
 Mel92.1 and Mel202 uveal melanoma cells were plated on 100 mm dishes 
and transfected using Lipofectamine RNAiMAX (Invitrogen) with siRNAs against ARF6, 
GEP100, or a control sequence (Qiagen) for 48 h. Transfectants were replated and 
retransfected for an additional 24 h in complete medium at a density of 10
5
 cells/well in 
8-well chambered coverglasses coated with 2% 225-bloom Gelatin (EM sciences) in 
ddH2O. After 24 h, monolayers were fixed for 20 min in 10% Neutral Buffered Formalin 
and then washed 3 times in 1× TBS. Antibodies against YAP (1A12) (Cell Signaling), -
catenin (BD Biosciences), and GNAQ (Abcam) were diluted 1/400, 1/100, and 1/250, 
respectively, in 1× TBS containing 1% BSA and 0.1% Saponin and applied to cells 
overnight at 4˚C. Wells were rinsed 4 times in 1× TBS, and 10 µg/ml Alexafluor 488-
conjugated anti-Mouse or anti-Rabbit IgG diluted in 1% BSA /0.1% Saponin was applied 
for 1 h at room temperature in a darkened box. Unbound secondary antibody was 
removed by 4 washes in 1× TBS, and DAPI anti-Fade medium was applied to the drained 
wells. Fields were randomly selected via the DAPI channel at 1200× with oil immersion. 
Z-stacked images (4 × 0.5 µm slices/field) were taken on an Olympus FV1000 confocal 
microscope at the University of Utah’s Cell Imaging core facility. The same procedure 
was also performed on untransfected Mel92.1 and Mel202 that were treated either with 5 
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µM NAV-2729/0.1% DMSO or 0.1% DMSO alone (control) for 1 h before being fixed 
and imaged as described above. 
Human uveal melanoma patient samples 
Primary human uveal melanoma samples were collected at the time of enucleation 
as previously described
60
. All samples were confirmed to be uveal melanomas by 
pathologic evaluation. Human ocular non-tumor samples were purchased from the Lions 
Eye Bank at the University of Utah. 
Orthotopic xenograft mouse model of uveal melanoma 
All animal studies were performed in accordance with a protocol approved by the 
University of Utah Institutional Animal Care and Use Committee. Athymic nude mice 
were purchased from Jackson Laboratories for this study. Mice were anesthetized with an 
intraperitoneal injection of a mixture of ketamine and xylazine. The eye was viewed 
under a dissecting microscope, and a sterile 30-gauge needle was used to puncture the 
posterior chamber of eye. 10
5
 cells in 5 µl were injected into the eye with a Hamilton 
syringe. For systemic treatment of NAV-2729, the compound was administered by 
intraperitoneal injection at a dosage of 30 mg/kg every day over a period of 5 weeks 
starting on the day of cell injection. After 5 weeks of tumor growth, mice were 
euthanized with CO2, and eyes were collected, fixed, embedded, sectioned, stained with 
H&E, and examined histologically for primary tumors by a pathologist who was blinded 




Recombinant Protein Expression and Purification 
All recombinant proteins for the ARF6 assay development were produced as N-
terminally His-tagged fusions in E. coli cultures and purified to apparent homogeneity as 
described previously
61
, including the truncated form of ARF6 (14-175), which does not 
require membranes or lipid vesicles for full activity, as well as the Sec7 domain-
containing fragments of GEP100 and ARNO that encompass residues 391-602 and 50-
255, respectively. The recombinant ARF6 purified in 50 mM Tris-HCl, pH 7.8, 2 mM 
MgCl2, 10% glycerol, 2 mM -mercaptoethanol, and approximately 150 mM imidazole 
was routinely converted into GDP-bound form by 2-h incubation in the presence of GDP 
in 10-fold molar excess relative to ARF6 and 5 mM EDTA.  Upon addition of MgCl2 to 
20 mM to terminate nucleotide exchange, two rounds of ultrafiltration, using Amicon 
Ultra-15-10K centrifugal filter units, were performed to remove free nucleotide and 
replace buffer system with 50 mM Tris-HCl, pH 7.5, 2 mM MgCl2, 10% glycerol, and 2 
mM -mercaptoethanol. 
Fluorometric Nucleotide Exchange Assay 
Our fluorometric nucleotide exchange assay for ARF6 and other small GTPases 
exploits fluorogenic nucleotide probe, GTP labeled with BODIPY FL, for monitoring 
GDP-to-GTP exchange at the nucleotide-binding site of ARF6. Intrinsic fluorescence of 
GTP-BODIPY is intramolecularly quenched in the unbound state but is significantly 
increased upon its binding to the target protein such as ARF6 or other small GTPases
62
. 
The fluorometric ARF6 nucleotide exchange assay used for high-throughput screening 
and routine inhibition assays was carried out in 96-well format using 100-µl aliquots of 
50 mM Tris-HCl, pH 7.5, 1 mM MgCl2, 0.01% Triton X-100, 2 mM -mercaptoethanol, 
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1% DMSO, 50 nM GTPBODIPY FL, 25 nM ARNO or GEP100, and 200 nM 
ARF6•GDP (unless indicated otherwise). Replacement of ARF6-bound GDP by GTP-
BODIPY FL was monitored by measuring increases in fluorescence intensity during a 
30-60 min time course using a plate reader at the excitation and emission wavelengths of 
490 nm and 520 nm, respectively. The high-throughput screening was performed at the 
University of Utah Drug Screening Resource using DiverSet library of compounds 
(ChemBridge) at 10 µM concentrations. The selectivity tests were conducted in the same 
format using small GTPases at 200 nM concentrations. All members of the selectivity 
panel, namely, RhoA, Rac1, Cdc24, and H-Ras that represent bacterially expressed N-
terminally His-tagged full-length recombinant proteins were purchased from 
Cytoskeleton, Inc. GTP-BODIPY FL was provided by Life Technologies. For the 
determination of signal-to-background ratio (S:B) and Z’-factor, the assay was performed 
using a 96-well plate with half of the wells supplemented with 10 µM GDP to estimate 
background fluorescence (B), which is equivalent to mean negative control value (µn), 
and another half with DMSO control to determine signal intensity (S), which is 
equivalent to mean positive control value (µp). Z’ factor value was calculated using the 
following formula: Z’=1 – 3(p + n)/(µp - µn), which also includes standard deviations 
for the positive and negative controls (p and n, respectively).  
Radiometric Nucleotide Exchange Assay 
The confirmation of HTS hits using a radiometric assay for ARF6 nucleotide 
exchange was carried out using 100-µl aliquots of same assay mix specified above for the 
fluorometric technique with the exception that 50 nM [
35
S]-GTPS (2 µCi/ml) was 
included to replace GTPBODIPY FL. Upon incubation for 30 min in the presence of test 
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articles, 200 µl of ice-cold assay buffer supplemented with 10 mM MgCl2 was added to 
stop the reaction followed by a rapid vacuum filtration of the samples using a 
nitrocellulose-bottomed 96-well plate, three washes of the membrane with the above stop 
solution, and scintillation counting to quantify GTPS bound to ARF6. 
Synthetic Methods 
All solvents and reagents were purchased from commercial sources and used 
without further purification unless otherwise noted. Reactions were monitored by TLC 
(thin layer chromatography) using 0.25 mm silica gel 60 F254 plates purchased from 





C spectra were recorded on a Varian Mercury 400 MHz instrument. Proton 
chemical shifts are expressed in parts per million (ppm) relative to TMS and calibrated 
using residual undeuterated solvent as internal reference. High-resolution mass spectra 
(HRMS) were recorded on Finnigan LTQ-FT, Thermo Electron Corporation. Compound 
purity was determined by an Agilent HP1050 instrument with a 4.6 mm × 150 mm Xterra 
C18 3.5 µm column. The flow rate was 1.2 mL/min, and the injection volume was 10 µl. 
HPLC conditions were as follows: mobile phase A, HPLC grade water (0.01% TFA); 
mobile phase B, HPLC grade acetonitrile (0.01% TFA); UV detector, 254 nm; 95% A/5% 
B to 0% A/100% B in 10 min, 100% B in 10−11 min, 100% B to 95% A/5% B in 11−13 
min, 95% A/5% B in 13−15 min. The final compound was ≥95% pure by HPLC. 
Synthesis of 2-benzyl-3-(4-chlorophenyl)-5-(4-nitrophenyl)-4H-pyrazolo[1,5-
a]pyrimidin-7-one (NAV-2729) involves refluxing 3-benzyl-4-(4-chlorophenyl)-1H-
pyrazol-5-amine and ethyl 3-(4-nitrophenyl)-3-oxo-propanoate in acetic acid for 16 h. To 
a suspension of 3-benzyl-4-(4-chlorophenyl)-1H-pyrazol-5-amine (3.0 g, 10.6 mmol) in 
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acetic acid (50 mL) was added ethyl 3-(4-nitrophenyl)-3-oxo-propanoate (2.5 g, 10.6 
mmol) at room temperature. The reaction mixture was heated at 120 ºC, 16 h. At the end 
of this period, the mixture was cooled to room temperature and the precipitate was 
collected, filtrated, and washed with acetic acid. The filter cake was triturated with 20% 
ethyl acetate in hexanes to provide NAV-2729 (3.40 g, 70%). TLC (CH2Cl2:MeOH, 95:5 
v/v): RF = 0.46;1H-NMR (400 MHz, DMSO-d6) (Figure S6J) 12.32 (s, 1H), 8.35 (d, 
J=8.5 Hz, 2H), 8.00 (d, J= 7.8 Hz, 2H), 7.50-7.34 (m, 4H), 7.28-7.00 (m, 5H), 6.10 (s, 
1H), 4.00 (s, 2H); 13C- NMR (400 MHz, DMSO-d6) (Figure S6K) 32.5, 96.4, 123.4, 
126.1, 128.2, 128.4, 129.3, 129.7, 131.7, 131.8, 138.5, 148.6, 155.6; HRMS (Figure S6L) 
(FT-ESI) (m/z): [M + H] + calculated for C25H18ClN4O3 457.1061, found 457.1078; 
HPLC (Figure S6M) purity, 96.9% (tR = 8.54 min). 
Molecular Modeling 
Molecular modeling was performed using program package ICM-Pro (MolSoft, 
LLS, San Diego, CA) that includes modules for homology modeling, docking, and virtual 
ligand screening. Homology model of N-terminally truncated ARF6 (13) structure was 
built using ARF1 (17) template extracted from a crystal structure of ternary ARF1 
(17)-GDP ARNO complex with inhibitor brefeldin A (Protein Data Bank ID 1S9D) 61. 
Then ARF1 structure in the ternary complex was replaced with the homology model of 
ARF6 and brefeldin A (BFA) was removed from the complex. Inhibitor NAV-2729 was 
docked into a binding site at the interface between ARF6 and ARNO. The preliminary 
model of ARF6-ARNO complex with NAV-2729 was refined using a binding site side 
chain optimization procedure available with ICM-Pro program. 
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Statistical Analyses 
Statistical analyses were performed using GraphPad Prism 6.0f. When two groups 
were being compared and the data appeared to be normally distributed, the Student’s t 
test was used. When multiple groups were being compared and the data were normally 
distributed, one-way ANOVA with Dunnett’s multiple comparisons test was performed, 
given that each treatment group was being compared to a single control group. When the 
data did not appear to be normally distributed, the Mann-Whitney U test was used. For 
statistical analyses of immunoblots, the density of each band was normalized to an 
internal control protein and then the ratio of the normalized density of the band from the 
experimental treatment to the normalized density of the paired control treatment band 
was obtained. Because these values are ratios, geometric means and 95% confidence 
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Figure 3.1 ARF6 is activated by oncogenic GNAQ and is required for uveal melanoma 
cell proliferation. (a) ARF6 protein levels in uveal melanomas as assessed by 
immunoblotting and densitometry; data represented as mean + SD; Welch’s unpaired 
two-tailed t test, **p < 0.01. (b) ARF6-GTP levels in uveal melanoma cells transfected 
with control (Ctrl), GNAQ#1, or GNAQ#2 siRNAs as assessed by immunoblotting and 
densitometry. The graph shows individual data points normalized to control along with 
geometric means and 95% confidence intervals (95% CI). 95% CIs that do not cross the 
dotted line at y=1 represent significant differences relative to the control at =0.05. (c) 
Uveal melanoma cell proliferation following transfection with Ctrl, ARF6#1, ARF6#2, or 
GNAQ siRNAs as assessed by DNA content using CyQUANT and a fluorescence 
microplate reader. FU: Fluorescence Units. (d) Anchorage-independent colony growth of 
cells transfected as in panel c. Percentage of cells normalized to control. Scale bar: 250 
µm. Data in panels c and d are represented as mean + SD, n=3 experiments. One-way 











Figure 3.2 ARF6 is necessary for oncogenic GNAQ-induced PLC/PKC, Rac/Rho, 
MAPK, and YAP activation. (a) Phosphoinositide turnover assay in uveal melanoma 
cells transfected with control (Ctrl), ARF6#1, ARF6#2, or GNAQ siRNAs. (b-e) Levels 
of p-MARCKS/MARCKS (b), Rac1-GTP/total Rac1 (c), RhoA-GTP/total RhoA (d), p-
ERK/ERK, p-p38/p38, p-JNK/JNK, and p-c-jun/c-jun (e) as assessed by immunoblotting 
from cells transfected as in panel a. (f) AP-1-mediated luciferase activities in uveal 
melanoma cells transfected with Ctrl, ARF6#1, ARF6#2, or GNAQ siRNAs. (g-i) 
Examination of YAP activation in uveal melanoma cells following treatment with ARF6 
or GNAQ siRNAs as illustrated by immunocytofluorescence (g), subcellular fractionation 
(h), and target gene expression (i) assays. Scale bar: 30 µm. Data are represented as mean 




















Figure 3.3 GNAQ and ARF6 control the subcellular localization and transactivation of 
-catenin in uveal melanoma cells. (a) Immunocytofluorescent staining for -catenin 
intracellular localization (green) and (b) subcellular fractionation (membrane, cytosol, 
and nucleus) in Mel92.1 and Mel202 uveal melanoma cells transfected with control 
(Ctrl), ARF6#1, ARF6#2, or GNAQ siRNAs. Scale bar: 30 µm. Individual data points 
that have been normalized to the control are shown along with geometric means and 95% 
confidence intervals (CIs). 95% CIs that do not cross the dotted line at y=1 represent 
significant differences relative to the control at 0.05. (c) -catenin-mediated luciferase 
activities in uveal melanoma cells transfected with Ctrl, ARF6#1, ARF6#2, or GNAQ 
siRNAs. Data are represented as mean + SD, n=3 experiments. One-way ANOVA, 
















Figure 3.4 ARF6 controls GNAQ trafficking between the plasma membrane and 
cytoplasmic vesicles/cytosol. (a) Immunocytofluorescent assays to assess GNAQ 
intracellular localization (green) following treatment of Mel92.1 and Mel202 cells with 
control (Ctrl) or ARF6 siRNA. Cells were counterstained with DAPI. Scale bar: 30 µm. 
(b) Immunoblots illustrating specific knockdown of ARF6 using the two ARF6 siRNAs 
used in subcellular fractionation studies shown in panel c. (c) Subcellular fractionation of 
GNAQ in Mel92.1 and Mel202 cells following treatment with two independent ARF6 
siRNAs and Ctrl siRNA. Individual data points that have been normalized to the control 
are shown along with geometric means and 95% confidence intervals (CIs). 95% CIs that 







Figure 3.5 Discovery, confirmation, and assessment of NAV-2729. (a) Principle of high-
throughput assay. (b) Structure and IC50 of NAV-2729. (c and d) Evaluation of NAV-
2729 inhibitory potency on fluorometric and radiometric nucleotide exchange assays (c) 
and on ARNO-mediated or GEP100-mediated ARF6 nucleotide exchange assays (d). (e) 
Assay for the effect of GTP on NAV-2729-stimulated dissociation of GTP-BODIPY. (f) 
Test for reversibility of NAV-2729 inhibition. (g) Model of ARF6-ARNO complex 
showing where NAV-2729 interacts with the complex. (h) Immunoblots of ARF-GTP 
pull-downs following treatment of Mel92.1 and Mel202 cells with NAV-2729 or vehicle 
(0). (i) Immunocytofluorescent assays to assess GNAQ intracellular localization (green) 
in uveal melanoma cells following NAV-2729 or DMSO (vehicle) treatment. (j) 
Subcellular fractionation of GNAQ in Mel92.1 and Mel202 cells treated with NAV-2729 
or DMSO (vehicle). (k) Anchorage-independent colony growth in Mel92.1 and Mel202 
cells treated with NAV-2729 or DMSO (vehicle). Scale bars: 250 µm. The graph shows 
the percentage of cells present relative to the control. Data are represented as mean + SD, 
n=3 experiments. Student’s two-tailed t test, ***p < 0.001. For panels h and j, individual 
data points have been normalized to DMSO (vehicle) and are shown along with 
geometric means and 95% confidence intervals (CIs). 95% CIs that do not cross the 







Figure 3.6 Silencing or pharmacological inhibition of ARF6 reduces uveal melanoma 
tumorigenesis in vivo. (a) Hematoxylin and eosin (H&E) stained sections from eyes 
engrafted with Mel202 cells expressing either control or ARF6 shRNAs. Scale bar: 500 
µm. (b and d) Left, number of eyes with and without a tumor (Fisher’s exact test). Right, 
primary tumor size (median; Mann-Whitney U test). *p < 0.05, ***p < 0.001. (c) H&E 
stained sections from eyes engrafted with Mel202 cells, followed by treatment of mice 
with either vehicle or NAV-2729. Scale bar: 200 µm. Arrows in panels A and C point to 






Supplementary Figure 3.1 Oncogenic GNAQ increases ARF6-GTP levels. Immunoblot 
of ARF6-GTP pull-downs from HEK293T cells that were transfected with MYC-tagged 
GNAQ
Q209L
, MYC-tagged wild type (WT) GNAQ, or vector. The graph shows individual 
data points normalized to control along with means and 95% confidence intervals (95% 
CI). 95% CIs that do not cross the dotted line at y=1 represent significant differences 





























Supplementary Figure 3.2 Wild type GNAQ and GNA11 uveal melanoma cells express 
WNT5A, which is necessary for ARF6 activation, Related to Figure 1. (A) WNT5A 
protein levels in uveal melanoma cells that carry GNAQ mutations [Q209L (Mel92.1 and 
Mel202) and Q209P (Mel270)] and wild type (Mel285 and Mel290). (B) Nucleotide 
sequencing for confirming GNAQ mutants and GNAQ wild type. LOX is a cutaneous 
melanoma cell which expresses WNT5A as a positive control. (C) Immunoblot of ARF6-
GTP pull-downs from uveal melanoma cells Mel285 and Mel290 transfected with control 





Supplementary Figure 3.3 Quantitation of western blots shown in Figure 2. (a-h) 
Quantitation of the activation of MARCKS (a), Rac1 (b), RhoA (c), ERK (d), p38 (e), 
JNK (f), c-jun (g), and the subcellular localization of YAP (h) from the immunoblots 
shown in Figure 2. The graphs show individual data points normalized to control along 
with means and 95% confidence intervals (95% CI). 95% CIs that do not cross the dotted 





Supplementary Figure 3.4 Ectopic expression of constitutively active ARF6 (ARF6
Q67L
) 
in HEK293T cells activates downstream oncogenic GNAQ signaling pathways. 
HEK293T cells were transfected with empty vector, MYC-tagged wild type (WT) ARF6, 
MYC-tagged ARF6
Q67L
, or MYC-tagged GNAQ
Q209L







 are expressed in HEK293T 
cells. (b) PLC activity in a phosphoinositide turnover assay. (c) Immunoblots of 
phosphorylated (p) ERK, p38, JNK, and c-jun. (d) Graph illustrating AP-1-mediated 
transcriptional activity in a luciferase reporter assay. (e) Immunoblots and quantitation 
showing the subcellular fractionation of YAP. (f) Graph illustrating YAP-mediated 
transcriptional activity in a luciferase reporter assay. For panels c and e, the graphs show 
individual data points normalized to control along with geometric means and 95% 
confidence intervals (95% CI). 95% CIs that do not cross the dotted line at y=1 represent 
significant differences relative to the control at =0.05. For panels b, d, and f, the data are 
represented as mean + SD, n=3 experiments. One-way ANOVA, Dunnett’s multiple 
comparisons test, **p < 0.01, ***p < 0.001. 
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Supplementary Figure 3.5 Knockdown of ARF6 or GNAQ does not alter the stability of 
-catenin in uveal melanoma cells and ectopic expression of ARF6Q67L or GNAQQ209L 
activates -catenin signaling. (a) Immunoblots showing total -catenin levels in Mel92.1 
and Mel202 cells following treatment with ARF6#1, ARF6#2, GNAQ, or control (Ctrl) 
siRNAs and quantitation of the immunoblots. (b) Immunoblots showing the subcellular 
fractionation of -catenin following transfection of HEK293T cells with empty vector, 
MYC-tagged wild type (WT) ARF6, MYC-tagged ARF6
Q67L
, or MYC-tagged 
GNAQ
Q209L
 and quantitation of the immunoblots. (c) -catenin-mediated transcriptional 
activity in a luciferase reporter assays following transfection of HEK293T cells with 




, or MYC-tagged 
GNAQ
Q209L
. (d) Mel92.1 and Mel202 cell proliferation assays following inhibition of -
catenin signaling with XAV939 or IWR-1-endo. Dotted horizontal line represents 
baseline DNA content before the addition of inhibitor. For panels a and b, the graphs 
show individual data points normalized to control along with geometric means and 95% 
confidence intervals (95% CI). 95% CIs that do not cross the dotted line at y=1 represent 
significant differences relative to the control at =0.05. For panels c and d, the data are 
represented as mean + SD, n=3 experiments. For panel c, one-way ANOVA, Dunnett’s 


















Supplementary Figure 3.6 An oncogenic GNAQ-GEP100 complex activates ARF6 and 
is necessary for uveal melanoma cell proliferation. (a) GEP100 and ARNO are expressed 
in uveal melanoma tissues. (b) ARF6-GTP levels in uveal melanoma cells transfected 
with control (Ctrl) or ARNO siRNAs as measured by pull-down assays and 
immunoblotting.  (c) ARF6-GTP levels in uveal melanoma cells transfected with Ctrl, 
GEP100#1, or GEP100#2 siRNAs. In panels b and c, individual data points that have 
been normalized to the control are shown along with geometric means and 95% 
confidence intervals (CIs). 95% CIs that do not cross the dotted line at y=1 represent 
significant differences relative to the control at 0.05. (d) Mel92.1 and Mel202 cell 
proliferation following transfection with Ctrl, GEP100#1, or GEP100#2 siRNAs as 
assessed by DNA content using CyQUANT and a fluorescence microplate reader. FU = 
Fluorescence units. (e) Anchorage-independent colony growth of cells transfected as in 
panel d. The graph shows the percentage of cells present relative to the control. Scale bar: 
250 µm. (f) Immunoblots of co-immunoprecipitated (IP) oncogenic GNAQ and GEP100 
in uveal melanoma cell extracts. IgG is negative control. Data in panels d and e are 
represented as mean + SD, n=3 experiments. One-way ANOVA, Dunnett’s multiple 






Supplementary Figure 3.7 Silencing of GEP100 inhibits oncogenic GNAQ-induced 
PLC/PKC and Rho/Rac signaling in uveal melanoma cells. (a-e) PLC activity in a 
phosphoinositide turnover assay (a) and activation of MARCKS (b), Rac1 (c), RhoA (d), 
and ERK, p38, JNK, and c-jun (e) as measured by densitometry of immunoblots 
following treatment of Mel92.1and Mel202 cells with two independent GEP100 siRNAs 
(GEP100#1 and GEP100#2) or Ctrl siRNA. (f) AP-1-mediated transcription in a 
luciferase activity assay following GEP100 knockdown in Mel92.1 and Mel202 cells 
using two independent siRNAs. For panels b-e, the graphs show individual data points 
normalized to control along with geometric means and 95% confidence intervals (95% 
CI). 95% CIs that do not cross the dotted line at y=1 represent significant differences 
relative to the control at =0.05. For panel f, the data are represented as mean + SD, n=3 











Supplementary Figure 3.8 Silencing of GEP100 inhibits oncogenic GNAQ-induced 
YAP and -catenin signaling in uveal melanoma cells. (a) Subcellular fractionation 
assays of YAP and (b) YAP target-gene mRNA levels following GEP100 silencing. (c) 
Subcellular fractionation assays of -catenin and (d) -catenin-mediated transcriptional 
activity in a luciferase reporter assay following GEP100 knockdown. For panels a and c, 
the graphs show individual data points normalized to control along with geometric means 
and 95% confidence intervals (95% CI). 95% CIs that do not cross the dotted line at y=1 
represent significant differences relative to the control at =0.05. For panels b and d, the 
data are represented as mean + SD, n=3 experiments. One-way ANOVA, Dunnett’s 







Supplementary Figure 3.9 GEP100 knockdown promotes localization of GNAQ to the 
plasma membrane. (a) Immunocytofluorescent staining and (b) subcellular fractionation 
of GNAQ in Mel92.1 and Mel202 cells that were transfected with GEP100 or control 
(Ctrl) siRNA. Scale bar: 30 µm. The graph shows individual data points normalized to 
control along with geometric means and 95% confidence intervals (95% CI). 95% CIs 
that do not cross the dotted line at y=1 represent significant differences relative to the 





Supplementary Figure 3.10 Development and validation of a fluorometric ARF6 
nucleotide exchange assay. (a) Dependence of signal intensity on the presence of ARF6 
and an ARF-GEF (ARNO). The arrow indicates the concentration of ARNO selected for 
the assay protocol. (b) Validation assay using GDP as a reference inhibitor. (c) 
Determination of signal-to-background ratio (S:B) and Z’-factor. (d) Stimulation of GTP-
BODIPY release from its complex with ARF6 by NAV-2729. (e-h) Non-inhibitory 
effects of NAV-2729 for other small GTPases (RhoA, Rac1, H-Ras, and Cdc42). (i) 
Molecular docking model of NAV-2729 binding to ARF6-ARFGEF complex showing 








Supplementary Figure 3.11 Characterization of NAV-2729. (a) Proton NMR spectra of 
NAV-2729. (b) Carbon-13 spectra of NAV-2729. (c) High Resolution Mass Spectra of 
NAV-2729. (d) HPLC of NAV-2729. 




The findings presented in this dissertation make two major contributions to our 
understanding of the molecular mechanisms that control tumor cell behavior. First, I 
demonstrate that ARF6 is a convergence point in the integration of competing signals that 
dictate -catenin function. WNT5A activates ARF6 to shift the plasma membrane pool of 
-catenin into the nucleus where it induces the transcription of genes that promote the 
invasion and metastasis of cutaneous melanoma, while SLIT2 inactivates ARF6, 
fortifying the association of -catenin with N-cadherin at the plasma membrane and 
inhibiting invasion and metastasis
1
. Consistent with our results, SLIT2-ROBO1 has been 
shown to inhibit canonical WNT signaling in mammary epithelial cells
2
. Our data show 
that both WNT5A and SLIT2-ROBO1 control invasion of cutaneous melanoma by 
modulating ARF6 activity, which regulates -catenin protein trafficking from the cell 
surface to nucleus. Although previous studies have primarily described WNT5A as an 
activator of noncanonical -catenin signaling3,4, there are several studies showing that 
WNT5A can stimulate -catenin signaling depending on cellular context4,5. The results 
for the role of -catenin in cutaneous melanoma are discordant. There are studies 
suggested that -catenin functions in the suppression of melanoma cell invasion and that  
  100 
the loss of -catenin is a prediction marker for a poor survival rate in melanoma patients6-
8
. Other studies have shown that activated -catenin signaling enhances melanoma 
metastasis
3,9,10
. However, these studies may overlook the dual functions of -catenin: 1) 
its role as a stabilizer of cell-cell interactions and 2) its role as an activator of 
transcription
11
. During the dynamic invasion process, -catenin function alternates 
between the cell surface and the nucleus. Therefore, -catenin cellular function should be 
evaluated based on subcellular localization using subcellular specific localized -catenin. 
We have shown that pharmacologic inhibition of ARF6 activity fortifies adherens 
junctions, inhibiting -catenin trafficking from plasma membrane to the nucleus, 
invasion, and metastasis of melanoma
1
. As a key molecule for controlling -catenin 
signaling induced by WNT5A, ARF6 will be an ideal therapeutic target for blocking 
invasion and metastasis of cutaneous melanoma. Here, I have explored a previously 
unknown role for ARF6 in WNT5A-mediated -catenin function and have shown that 
this signaling pathway controls invasion and metastasis. Therefore, the study for ARF6 
offers a new therapeutic approach in WNT/-catenin-driven cancers. 
The second major contribution of this work involves our understanding of the role 
of ARF6 in uveal melanoma. Using biochemical tools, cellular assays, and orthotopic 
xenograft mouse models, I demonstrate that an oncogenic GNAQ-GEP100-ARF6 
complex controls multiple signaling pathways to promote the proliferation of uveal 
melanoma cancer cells and tumorigenesis. I show that ARF6 is an immediate 
downstream effector of a GNAQ
Q209L
-GEP100 complex that controls the activation of all 
the currently known GNAQ-mediated oncogenic signaling pathways by regulating the 
intracellular trafficking of GNAQ. I also show that the GNAQ-GEP100-ARF6 complex 
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controls -catenin signaling, thus identifying an additional pathway regulated by 
oncogenic GNAQ. Previously, several investigations have showed that constitutively 
active mutants of GNAI (encoding Gi), GNAS (encoding Gs), GNAQ (encoding Gq), 
GNAO1 (encoding Go), and GNA12 (encoding G12) induce the transformation of cells, 
which suggests that activating mutations in G proteins have a potential to promote 
tumorigenesis and enhance proliferation
12
. Recently, intensive genomic research in 
human cancers has confirmed the mutations of various G proteins in addition to 
GNAQ/GNA11. For example, mutations in GNAS occur in pituitary tumours (28%), 
thyroid adenomas (5%), colon cancer (4%), pancreatic tumours (12%), hepatocellular 
carcinoma (2%), and parathyroid cancer (3%)
13
. Similar to activating mutations in 
GNAQ or GNA11 in uveal melanoma, these major mutations in GNAS mainly occur in 
two amino acids, R201 or Q227, which result in constitutive activity by decreasing 
GTPase activity
13
. Interestingly, these activating mutations in GNAS are frequently found 
in a specific tumor type such as pancreatic cancer. GNAS mutations are found in 66% of 
intraductal papillary mucinous neoplasms (IPMNs), which are precursors of pancreatic 
adenocarcinoma, suggesting that constitutively active GNAS-driven signaling pathways 
contribute to pancreatic neoplasia
14,15
. Although the presence of activating mutations in 
GNAS, GNAQ, and GNA11 in multiple cancers is clear, further study will be required to 
understand how these activating mutations in G proteins induce tumorigenesis. Based on 
the previous report that ARF6 is originally found as a cofactor for the cholera toxin-
catalyzed ADP ribosylation of GNAS
16
, an intriguing hypothesis is that ARF6 acts as a 
downstream signaling node in GNAS driven-cancers. I further postulate that targeting 
ARF6 or other similar nodes might not only be efficacious for treating GNAQ, GNA11, 
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or GNAS-mediated cancers but also for the multiple cancers controlled by other G 
protein mutations. Further experiments will be required to test these crucial hypotheses. 
Recently, the results of deep genome sequencing in multiple human cancers have 
indicated the loss of function for SLIT-ROBO through allelic deletion or 
hypermethylation in their promoter
17
, suggesting that SLIT-ROBO signaling plays 
important roles in tumorigenesis, cancer progression, and metastasis. Also, the loss of 
ROBO1 expression in uveal melanoma helps to identify patients at high risk for 
metastasis
18
. Based on our findings from cutaneous melanoma, it will be important to 
identify the key molecular components of the SLIT-ROBO-ARF6 signaling axis and their 
role in uveal melanoma invasion and metastasis. 
Although over 80% of uveal melanomas harbor activating mutations in GNAQ or 
GNA11
19
, the oncogenic driver in uveal melanomas that do not possess GNAQ or 
GNA11 mutations is unknown. According to our preliminary data, uveal melanoma cells 
that have GNAQ mutations do not express WNT5A, while tumor cells that possess wild 
type GNAQ and GNA11 express high levels of WNT5A. Interestingly, WNT5A is 
necessary for ARF6 activation in wild type GNAQ and GNA11 uveal melanoma cells. 
Frizzled receptors contain seven transmembrane domains and are classified as GPCRs
20
. 
Previous studies have shown that the differential effects of Gα proteins either increase or 
decrease WNT/-catenin signaling dependent on the subtype of G proteins21. 
Specifically, it has been shown that GNAQ signaling contributes to WNT-mediated 
melanoma invasion and metastasis through frizzled receptors
22,23
. Therefore, I 
hypothesize that WNT5A, acting through a frizzled receptor and G protein/GEF 
complex, activates ARF6, which then this transduces the downstream oncogenic 
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signaling pathways in GNAQ and GNA11 wild type uveal melanoma cells. Future 
studies could test this hypothesis and help define whether there is a common WNT-G-
ARF6 signaling cascade in both cutaneous and uveal melanoma. This discovery suggests 
that a more effective therapeutic approach might be to target ARF6 directly, thereby 
inhibiting WNT/-catenin signaling as well as all of the known downstream GNAQ-
mediated oncogenic pathways with a single inhibitor. To this end, we have begun to 
identify direct inhibitors of ARF6 and show that one of these, NAV-2729, can inhibit 
tumor formation and growth in a orthotopic xenograft model of uveal melanoma. 
In summary, our work provides the first example of an endogenous canonical 
WNT5A signaling pathway in a mammalian system and a mechanistic explanation, 
through ARF6, for how this typically noncanonical WNT stimulates -catenin-mediated 
transcription. Previously, WNTs had not been shown to affect junctional -catenin. We 
demonstrate that WNT5A draws upon this cadherin-bound pool of -catenin to boost 
transcription. Pharmacologic inhibition of ARF6 activation is also effective in opposing 
this WNT5A/-catenin pathway and inhibits spontaneous metastasis of melanoma in 
vivo. Thus, targeting ARF6 may be an effective approach for inhibiting WNT-driven 
cancers. We also show that oncogenic GNAQ, a Gq protein, induces its multiple 
signaling pathways through a single actionable node—the small GTPase ARF6. These 
results not only reveal the mechanism by which a proximal downstream effector of an 
oncogene can simultaneously influence multiple divergent signaling pathways but also 
suggest that targeting such nodes could be an efficacious approach for treating cancers 
driven by oncogenes that have proven recalcitrant to direct inhibition. 
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